| 2025-11-12 |
详情>>
股本变动：
变动后总股本6896.42万股
|
| 2025-11-12 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-0.59美元,归母净利润-3306.8万美元,同比去年增长-47.64%
|
| 2025-08-13 |
详情>>
业绩披露：
2025年中报每股收益-0.32美元,归母净利润-1561.4万美元,同比去年增长-5%
|
| 2025-05-15 |
详情>>
业绩披露：
2025年一季报每股收益-0.24美元,归母净利润-819.4万美元,同比去年增长-15.31%
|
| 2025-04-02 |
股东大会：
将于2025-04-30召开股东大会
会议内容 ▼▲
- 1.Elect nine director nominees to our board of directors (the “Board”);
2.Ratify, on an advisory basis, the appointment of Ernst & Young, LLP as the Company’s independent public accounting firm for the fiscal year ending December 31, 2025;
3.Approve, on an advisory basis, the compensation of the Company’s named executive officers;
4.Approve, pursuant to the Nasdaq Listing Rules, the conversion of the Company’s Series A Preferred Stock into shares of Common Stock;
5.Approve one or more adjournments of the Annual Meeting to solicit additional proxies if necessary.
|
| 2025-03-31 |
详情>>
业绩披露：
2024年年报每股收益-2.15美元,归母净利润-5753.2万美元,同比去年增长-476.13%
|
| 2024-11-12 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-0.88美元,归母净利润-2239.7万美元,同比去年增长-331.46%
|
| 2024-08-13 |
详情>>
业绩披露：
2024年中报每股收益-0.59美元,归母净利润-1487.1万美元,同比去年增长-38.31%
|
| 2024-05-10 |
详情>>
业绩披露：
2024年一季报每股收益-0.29美元,归母净利润-710.6万美元,同比去年增长-22.71%
|
| 2024-04-29 |
股东大会：
将于2024-06-11召开股东大会
会议内容 ▼▲
- 1.Elect the seven director nominees named in the Proxy Statement;
2.Ratify the appointment of Ernst & Young, LLP as the Company’s independent public accounting firm for the fiscal year ending December 31, 2024;
3.Approve, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the accompanying Proxy Statement;
4.Approve, pursuant to the Nasdaq Listing Rules, the potential issuance of shares of common stock to Lincoln Park Capital Fund, LLC in excess of 19.99% of our outstanding common stock;
5.Approve an amendment to the Company’s Amended and Restated Certificate of Incorporation to provide for the exculpation of officers;
6.Approve an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of the Company’s common stock from 75 million shares to 125 million shares.
|
| 2024-03-08 |
详情>>
业绩披露：
2023年年报每股收益-0.46美元,归母净利润-998.6万美元,同比去年增长-155.83%
|
| 2023-11-13 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-0.25美元,归母净利润-519.1万美元,同比去年增长67.66%
|
| 2023-08-11 |
详情>>
业绩披露：
2023年中报每股收益-0.51美元,归母净利润-1075.2万美元,同比去年增长6.68%
|
| 2023-05-01 |
股东大会：
将于2023-06-06召开股东大会
会议内容 ▼▲
- 1.To elect six directors named in the Proxy Statement, each to serve for a one-year term;
2.To ratify the appointment of our independent registered public accounting firm for 2023;
3.To approve (on an advisory basis) whether an advisory vote on the compensation of our named executive officers should occur once every one, two or three years
|
| 2022-04-27 |
股东大会：
将于2022-06-13召开股东大会
会议内容 ▼▲
- 1.to elect seven directors named in the Proxy Statement, each to serve for a one-year term;
2.to ratify the appointment of our independent registered public accounting firm for 2022.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-26 |
股东大会：
将于2021-06-07召开股东大会
会议内容 ▼▲
- 1.to elect seven directors named in the Proxy Statement, each to serve for a one-year term;
2.to ratify the appointment of our independent registered public accounting firm for 2021;
3.to approve our named executive officers’ compensation in an advisory vote.
|
| 2020-10-02 |
股东大会：
将于2020-11-02召开股东大会
会议内容 ▼▲
- 1.to consider and vote upon a proposal to approve the issuance of shares of Rexahn common stock, $0.0001 par value per share (“Rexahn common stock”), to stockholders of Ocuphire pursuant to the terms of the Agreement and Plan of Merger and Reorganization, dated as of June 17, 2020, by and among Rexahn, Merger Sub and Ocuphire, as amended by the First Amendment to Agreement and Plan of Merger and Reorganization dated June 29, 2020, a copy of which is attached as Annex A to this proxy statement/prospectus/information statement (as amended, the “Merger Agreement”), and the change of control of Rexahn resulting from the merger under The Nasdaq Stock Market LLC rules;
2.to consider and vote upon an amendment to the amended and restated certificate of incorporation of Rexahn, as amended (the “Rexahn Certificate of Incorporation”), to effect a reverse stock split of Rexahn common stock, at a ratio within the range of 1-for-3 to 1-for-5, with such specific ratio to be approved by the Rexahn Board, in the form attached as Annex B to this proxy statement/prospectus/information statement;
3.to consider and vote upon an amendment to the Rexahn Certificate of Incorporation to change the corporate name of Rexahn from “Rexahn Pharmaceuticals, Inc.” to “Ocuphire Pharma, Inc.”, in the form attached as Annex C to this proxy statement/prospectus/information statement;
4.to consider and vote upon a proposal to approve the adoption of the Ocuphire Pharma, Inc. 2020 Equity Incentive Plan in the form attached as Annex D to this proxy statement/prospectus/information statement (the “Ocuphire 2020 Plan”);
5.to consider and vote upon a proposal to approve the issuance of: (i) shares of Rexahn common stock upon the exercise of the Investor Warrants to be issued in the Pre-Merger Financing, and (ii) additional shares of Rexahn common stock that may be issued following the closing of the Pre-Merger Financing, in each case pursuant to the Amended and Restated Securities Purchase Agreement, dated as of June 29, 2020, by and among Rexahn, Ocuphire and the investors party thereto, and as required by and in accordance with Nasdaq Listing Rule 5635;
6.to consider and vote upon an adjournment of the Rexahn special meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposal No. 1, 2, 3, 4 or 5;
7.to transact such other business as may properly come before the Rexahn special meeting or any adjournment or postponement thereof.
|
| 2019-04-29 |
股东大会：
将于2019-06-06召开股东大会
会议内容 ▼▲
- 1.to elect as directors the seven nominees named in the accompanying proxy statement to a term of one year each, or until their successors have been elected and qualified;
2.to ratify the appointment of Baker Tilly Virchow Krause, LLP as the independent registered public accounting firm of the Company for the year ending December 31, 2019;
3.to consider and take action upon such other matters as may properly come before the Annual Meeting or any postponement or adjournment thereof.
|
| 2019-04-12 |
详情>>
拆分方案：
每12.0000合并分成1.0000股
|
| 2019-02-14 |
股东大会：
将于2019-03-26召开股东大会
会议内容 ▼▲
- 1.to approve an amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended, to effect a reverse stock split of the Company’s common stock at a ratio within the range of 1:5 to 1:15, as determined by the Board of Directors and with such reverse stock split to be effected at such time and date, if at all, as determined by the Board of Directors in its sole discretion;
2.to approve the adjournment of the Special Meeting, if necessary, if a quorum is present, to solicit additional proxies if there are not sufficient votes to approve Proposal 1;
3.to consider and take action upon such other matters as may properly come before the Special Meeting or any postponement or adjournment thereof.
|
| 2019-01-29 |
详情>>
内部人交易：
Swirsky Douglas J等共交易2笔
|
| 2018-07-23 |
股东大会：
将于2018-08-30召开股东大会
会议内容 ▼▲
- 1.to approve an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 50,000,000 to 75,000,000;
2.to approve the adjournment of the Special Meeting, if necessary, if a quorum is present, to solicit additional proxies if there are not sufficient votes to approve Proposal 1;
3.to consider and take action upon such other matters as may properly come before the Special Meeting or any postponement or adjournment thereof.
|
| 2018-04-23 |
股东大会：
将于2018-06-14召开股东大会
会议内容 ▼▲
- 1.to elect as directors the five nominees named in the accompanying proxy statement to a term of one year each, or until their successors have been elected and qualified;
2.to ratify the appointment of Baker Tilly Virchow Krause, LLP as the independent registered public accounting firm of the Company for the year ending December 31, 2018;
3.to approve an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 50,000,000 to 100,000,000;
4.to approve the adjournment of the Annual Meeting, if necessary, if a quorum is present, to solicit additional proxies if there are not sufficient votes to approve Proposal 3;
5.to consider and take action upon such other matters as may properly come before the Annual Meeting or any postponement or adjournment thereof.
|
| 2017-04-13 |
详情>>
拆分方案：
每10.0000合并分成1.0000股
|
| 2017-02-24 |
股东大会：
将于2017-04-11召开股东大会
会议内容 ▼▲
- 1.to elect as directors the seven nominees named in the accompanying proxy statement to a term of one year each, or until their successors have been elected and qualified;
2.to ratify the appointment of Baker Tilly Virchow Krause, LLP as the independent registered public accounting firm of the Company for the year ending December 31, 2017;
3.to approve, by non-binding vote, the Company’s executive compensation;
4.to recommend, by non-binding vote, the frequency of future non-binding votes on executive compensation;
5.to approve an amendment to the Rexahn Pharmaceuticals, Inc. 2013 Stock Option Plan, as amended and restated, to increase the number of shares of common stock reserved for issuance thereunder from 17,000,000 to 34,000,000;
6.to approve an amendment to the Company’s Amended and Restated Certificate of Incorporation (in the event it is deemed by the Board of Directors to be advisable) to effect a reverse stock split of the Company’s common stock at a ratio within the range of 1:5 to 1:20, as determined by the Board of Directors, together with a corresponding proportional reduction in the number of authorized shares of the Company’s capital stock;
7.to approve the adjournment of the Annual Meeting, if necessary, if a quorum is present, to solicit additional proxies if there are not sufficient votes to approve Proposal 6;
8.to consider and take action upon such other matters as may properly come before the Annual Meeting or any postponement or adjournment thereof.
|
| 2016-04-18 |
股东大会：
将于2016-06-09召开股东大会
会议内容 ▼▲
- 1.to elect as directors the seven nominees named in the accompanying proxy statement to a term of one year each, or until their successors have been elected and qualified;
2.to ratify the appointment of Baker Tilly Virchow Krause, LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2016;
3.to approve an amendment and restatement of the Rexahn Pharmaceuticals, Inc. 2013 Stock Option Plan (the “2013 Plan”), including to provide for awards of restricted stock or restricted stock units;
4.to consider and take action upon such other matters as may properly come before the Annual Meeting or any postponement or adjournment thereof.
|